EUVIMEDEUVIMED entdecken
Crossref

Milestone cancer vaccine success leaves hard questions unanswered

Jocelyn Kaiser

Science · 29.10.2026 · 394 (6823) · 478-479

DOI: 10.1126/science.aen6356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 29.10.2026. Verfasst von Jocelyn Kaiser. Hauptthemen laut MEDLINE: Cancer Vaccines, Melanoma, mRNA Vaccines, Neoplasm Recurrence, Local.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA vaccine from Merck and Moderna slashes risk of melanoma’s return, but why remains unclear

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesMelanomamRNA VaccinesNeoplasm Recurrence, LocalHumansClinical Trials, Phase III as Topic

Substanzen

Cancer VaccinesmRNA Vaccines

Zitieren

APA

Kaiser, J. (2026). Milestone cancer vaccine success leaves hard questions unanswered. Science, 394(6823), 478-479. https://doi.org/10.1126/science.aen6356

Vancouver

Kaiser J. Milestone cancer vaccine success leaves hard questions unanswered. Science. 2026;394(6823):478-479. doi:10.1126/science.aen6356

BibTeX
@article{Kaiser2026,
  author = {Kaiser, Jocelyn},
  title = {Milestone cancer vaccine success leaves hard questions unanswered},
  journal = {Science},
  year = {2026},
  volume = {394},
  number = {6823},
  pages = {478--479},
  doi = {10.1126/science.aen6356}
}
Kostenlos starten →